Cortexyme Alzheimer’s Study Fails; Drug Slows Cognitive Decline In Some Patients
Subpopulation Efficacy Limited To One Of Two Primary Endpoints
Atuzaginstat targets a bacteria associated with Alzheimer’s disease. The higher of two doses showed a 57% slowing in cognitive decline in the Phase II/III GAIN trial in mild to moderate patients with P. gingivalis infection confirmed by saliva test.
